Great exposure. ADR have been supplying the top Asthma centres...

Great exposure.
ADR have been supplying the top Asthma centres in small numbers for years and have got not traction.
AZ/ADR have had a number of initiatives in the UK with Asthma in the community setting with no traction.
This is a repeat of trials done 10-15 years ago which already show the benefits on outcomes. This trial will recomfirm what is known.
What needs to change is 1) Funding 2) GP / community Dr engagement 3) Patient engagment 4) Pharma to see this adds value.
What it won't do is make any difference to success in the US which is the make or break market for ADR.
While giving credit for an interesting little project I still stand behind the fact its a distraction for ADRs limited resources when ALL their focus needs to be in the US.
Drip feeding ADR off small clinical trial revenues does not make a business and hides the underlying issues that have dogged the business since the IPO in 2015.

The new CEO needs to be bold, kill everything not US, put an aggressive plan together and go for it. Make it or break it!

Whats doing to make that really tough is getting enough funding out of the Austalia market that loves ADR but has grown tired and exhausted over the last 20 years; where retail investors have been diluted to death and the top 5 holders have everything to loose but nothing in terms of adding liquidity to move the SP to anything near where it needs to be to get a return. If there are "players" in the game then no chance.
While it would kill us the options of delisting or listing in the US may be the best options for ADR as a buisness but the worst option for investors.